ATE544451T1 - Pharmazeutisch aktive isoindolin-derivate - Google Patents

Pharmazeutisch aktive isoindolin-derivate

Info

Publication number
ATE544451T1
ATE544451T1 AT10176390T AT10176390T ATE544451T1 AT E544451 T1 ATE544451 T1 AT E544451T1 AT 10176390 T AT10176390 T AT 10176390T AT 10176390 T AT10176390 T AT 10176390T AT E544451 T1 ATE544451 T1 AT E544451T1
Authority
AT
Austria
Prior art keywords
pharmaceutically active
isoindoline derivatives
active isoindoline
derivatives
oxoisoindoline
Prior art date
Application number
AT10176390T
Other languages
English (en)
Inventor
Hon-Wah Man
George W Muller
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE544451T1 publication Critical patent/ATE544451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT10176390T 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate ATE544451T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16516899P 1999-11-12 1999-11-12
US59034400A 2000-06-08 2000-06-08
US09/708,199 US6667316B1 (en) 1999-11-12 2000-11-08 Pharmaceutically active isoindoline derivatives

Publications (1)

Publication Number Publication Date
ATE544451T1 true ATE544451T1 (de) 2012-02-15

Family

ID=27389110

Family Applications (4)

Application Number Title Priority Date Filing Date
AT10176420T ATE544452T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate
AT00977095T ATE357913T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch-aktive isoindolin-derivate
AT10176390T ATE544451T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate
AT06009632T ATE506058T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT10176420T ATE544452T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate
AT00977095T ATE357913T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch-aktive isoindolin-derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06009632T ATE506058T1 (de) 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate

Country Status (19)

Country Link
US (1) US6667316B1 (de)
EP (4) EP1228071B8 (de)
JP (1) JP5116201B2 (de)
CN (1) CN1325497C (de)
AT (4) ATE544452T1 (de)
AU (2) AU782409B2 (de)
CA (1) CA2392081C (de)
CY (2) CY1107610T1 (de)
DE (1) DE60034139T2 (de)
DK (2) DK1228071T3 (de)
ES (4) ES2381174T3 (de)
FI (1) FI119931B (de)
HK (2) HK1049158A1 (de)
MX (1) MXPA02004793A (de)
NO (2) NO323633B1 (de)
NZ (1) NZ519459A (de)
PT (2) PT2263669E (de)
SI (1) SI1228071T1 (de)
WO (1) WO2001034606A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
ES2315435T3 (es) * 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
AU2002257195A1 (en) 2001-04-23 2002-11-05 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
DE60231989D1 (de) * 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003234624B8 (en) 2002-05-17 2009-03-12 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
KR20050056247A (ko) 2002-10-15 2005-06-14 셀진 코포레이션 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004486A (es) * 2002-10-31 2005-07-26 Celgene Corp Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular.
NZ540384A (en) * 2002-11-06 2008-06-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
CA2505131A1 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
DE60330187D1 (de) 2002-12-30 2009-12-31 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
EP1605935A4 (de) * 2003-03-06 2009-05-20 Celgene Corp Verfahren zur verwendung von und zusammensetzungen mit selektiven zyotkin-hemmenden arzneimitteln zur behandlung und versorgung von erkrankungen des zentralen nervensystems
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
AU2004220456B2 (en) * 2003-03-12 2010-10-14 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
CA2518584A1 (en) 2003-03-12 2004-09-23 Celgene Corporation 7-amino- isoindolyl compounds and their pharmaceutical uses
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2007524656A (ja) * 2003-10-23 2007-08-30 セルジーン・コーポレーション 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
EP1744748A4 (de) * 2004-04-14 2009-08-12 Celgene Corp Verfahren zur verwendung von selektiven zytokin-hemmenden arzneimitteln und diese enthaltende zusammensetzungen zur behandlung und versorgung von myelodysplastischen syndromen
CN1972684A (zh) * 2004-04-23 2007-05-30 细胞基因公司 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
EP1750697A4 (de) * 2004-05-05 2009-08-26 Celgene Corp Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
US20090010886A1 (en) * 2004-05-05 2009-01-08 Celgene Corporation Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN101052630A (zh) 2004-09-03 2007-10-10 细胞基因公司 取代的杂环化合物和其用途
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
KR20070092276A (ko) * 2004-12-13 2007-09-12 셀진 코포레이션 Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CN102036663A (zh) * 2008-03-24 2011-04-27 细胞基因公司 用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎
US8563580B2 (en) * 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
US9040715B2 (en) 2008-09-23 2015-05-26 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
PE20120580A1 (es) 2009-02-10 2012-05-23 Celgene Corp Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
CN107964016B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
ME01883B (me) 2009-06-18 2014-12-20 Concert Pharmaceuticals Inc Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa
CN102639498A (zh) * 2009-10-09 2012-08-15 细胞基因公司 制备2-(1-苯乙基)异吲哚啉-1-酮化合物的方法
RU2012131164A (ru) * 2009-12-22 2014-01-27 Селджин Корпорейшн (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
CA2794096A1 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
JP6132773B2 (ja) * 2011-01-10 2017-05-24 セルジーン コーポレイション Ｐｄｅ４及び／又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体
MX2013007959A (es) 2011-01-10 2013-12-06 Celgene Corp Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
ES2868231T3 (es) 2011-03-07 2021-10-21 Amgen Europe Gmbh Métodos de tratamiento de enfermedades usando compuestos de isoindolina
AU2012296543B2 (en) 2011-08-16 2016-08-11 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
ES2803524T3 (es) * 2011-09-14 2021-01-27 Amgen Europe Gmbh Formulaciones de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida del ácido ciclopropanocarboxílico
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
US10287248B2 (en) * 2015-03-19 2019-05-14 Cipla Limited Process for the preparation of apremilast
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
AU2017317123B9 (en) * 2016-08-22 2021-11-25 Medshine Discovery Inc. PDE4 inhibitor
CN107698484B (zh) * 2017-11-13 2020-05-19 广东中科药物研究有限公司 一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en) 2018-01-17 2019-07-25 Cadila Healthcare Limited Pharmaceutical compositions for treatment of vitiligo
AU2019254962C1 (en) 2018-04-17 2023-04-27 Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd Isoindole derivatives
WO2020020101A1 (zh) * 2018-07-22 2020-01-30 上海星叶医药科技有限公司 苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) * 2019-03-15 2022-08-02 华南师范大学 一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) * 2020-01-09 2023-01-17 常州大学 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
CN117203196A (zh) * 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv) 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
JP3131225B2 (ja) 1995-07-26 2001-01-31 ファイザー・インコーポレーテッド Ｎ−（アロイル）グリシンヒドロキサム酸誘導体および関連化合物
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
CA2263154A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
ES2315435T3 (es) 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
CZ299873B6 (cs) * 1997-07-31 2008-12-17 Celgene Corporation Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
NZ519459A (en) 2003-11-28
EP2255801A1 (de) 2010-12-01
EP1698334A1 (de) 2006-09-06
PT1228071E (pt) 2007-05-31
NO20071490L (no) 2002-07-08
NO20022223D0 (no) 2002-05-08
MXPA02004793A (es) 2003-10-14
ATE357913T1 (de) 2007-04-15
DK2263669T3 (da) 2012-04-23
ES2363933T3 (es) 2011-08-19
CN1420889A (zh) 2003-05-28
EP2255801B1 (de) 2012-02-08
ES2282147T3 (es) 2007-10-16
ES2380574T3 (es) 2012-05-16
EP2263669B1 (de) 2012-02-08
DK1228071T3 (da) 2007-08-06
ATE506058T1 (de) 2011-05-15
ES2381174T3 (es) 2012-05-23
US6667316B1 (en) 2003-12-23
EP1228071B8 (de) 2012-02-29
NO20022223L (no) 2002-07-08
EP1698334B1 (de) 2011-04-20
CA2392081A1 (en) 2001-05-17
SI1228071T1 (sl) 2007-08-31
AU2005202964B2 (en) 2007-11-22
FI20020892A0 (fi) 2002-05-10
EP1228071A4 (de) 2002-12-04
DE60034139D1 (de) 2007-05-10
JP2004500346A (ja) 2004-01-08
NO323633B1 (no) 2007-06-18
CY1112707T1 (el) 2016-02-10
PT2263669E (pt) 2012-04-23
FI119931B (fi) 2009-05-15
NO336210B1 (no) 2015-06-15
CA2392081C (en) 2010-01-05
AU1478001A (en) 2001-06-06
CY1107610T1 (el) 2013-03-13
HK1049158A1 (zh) 2003-05-02
EP1228071B1 (de) 2007-03-28
EP2263669A1 (de) 2010-12-22
ATE544452T1 (de) 2012-02-15
AU782409B2 (en) 2005-07-28
JP5116201B2 (ja) 2013-01-09
FI20020892A (fi) 2002-06-20
DE60034139T2 (de) 2007-12-06
CN1325497C (zh) 2007-07-11
AU2005202964A1 (en) 2005-08-11
EP1228071A1 (de) 2002-08-07
WO2001034606A1 (en) 2001-05-17
HK1053467A1 (en) 2003-10-24

Similar Documents

Publication Publication Date Title
ATE544451T1 (de) Pharmazeutisch aktive isoindolin-derivate
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
DE60045168D1 (de) Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
DK1206261T3 (da) Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
DK3449934T3 (da) Behandling af glycogenlagringssygdom type II
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK0998287T3 (da) Anvendelse af levobupivacain
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
SE9902742D0 (sv) New pharmaceutical formultion
ITMO990002A0 (it) Articolatore per odontotecnica.
ATE302582T1 (de) Haartonikum mit l-arginin als wirkstoff
IT1306706B1 (it) Articolatore perfezionato per la realizzazione di modelli in gesso.
IT1309464B1 (it) Apparecchio per laserterapia.
DK1086695T3 (da) Antivirale præparater omfattende yohimbin som aktivt princip
RU2000104099A (ru) Средство для локальной противоревматической терапии
IT1311630B1 (it) Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.
ITBO990038A0 (it) Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .
ES1044269Y (es) Mesa camilla desmontable.
ES1043536Y (es) Calzado perfeccionado.
ES1042703Y (es) "cuadro perfeccionado".
IT1316492B1 (it) Accessorio polifunzionale, particolarmente per la cura dell'acquario.
ITBS990062V0 (it) Trave composta per solaio.
ES1042364Y (es) "pañal perfeccionado".
ITTO990194V0 (it) Ciabatta monouso.